Christina Bothou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christina Bothou has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Dimitrios T. Papadimitriou
Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larisa, Greece
5 shared publications A. Papadimitriou
Division of pediatric endocrinology, Attikon university hospital, Athens, Greece
3 shared publications- Constanze Hantel
Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland
3 shared publications - Felix Beuschlein
Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich and University of Zurich, Zurich, Switzerland
3 shared publications Nicholas Angelopoulos
Endocrine Hospital, Unit, Metropolitan Greece, Athens, Greece
3 shared publicationsSarantis Livadas
Endocrine Unit, Metropolitan Hospital, Athens, Greece
3 shared publications
Latest Publications
- Open Access
- 23 October 2024
- Published by University Library J. C. Senckenberg
Einfluss der systemischen Inflammation für die portalvenöse und systemische Hämodynamik bei Patienten mit Leberzirrhose - Implikationen für hepatische Dekompensation
Systemic inflammation is known to be a key player in the pathogenesis of the development of cirrhosis and consequent liver failure. However, the role of inflammation in the cascade of classical liver decompensation is not fully understood. This research project, part of a series of projects investigating hepatic decompensation in a large cohort of patients, aims to elucidate the interplay between systemic inflammation, hemodynamics, and anemia in decompensation in cirrhosis. The study population consisted of consecutively followed outpatients with advanced liver fibrosis or cirrhosis. We approached our research question by performing a post hoc analysis for potential parameters associated with liver decompensation and/or hospitalization. In total, we analyzed data from 338 patients, with 50/338 (15%) hospitalized for decompensated cirrhosis during a median follow-up of six months. In a first step, we performed a univariate analysis, which showed that active alcoholism (p = 0.002), Model of End-Stage Liver Disease (MELD) score (p = 0.00002), serum IL-6 concentration (p = 0.006), heart rate (p = 0.03), low arterial blood pressure (p < 0.05), maximal portal venous flow (p = 0.008), and low hemoglobin concentration (p < 0.00001) were associated with hospitalization during follow-up. Subsequent multivariate analysis showed an independent association of low hemoglobin (OR = 0.62, 95% CI = 0.51-0.78, p = 0.001) and serum IL-6 concentration (OR = 1.02, 95% CI = 1.01-1.04, p = 0.03), but not hemodynamic parameters, with liver decompensation. An inverse correlation between hemoglobin concentration and portal venous flow (R = -0.362, p < 0.0001) was observed in non-hospitalized patients. The accuracy of baseline hemoglobin levels in predicting hospitalization (area under the curve-AUC = 0.84, p < 0.000001) was high. In conclusion, our study showed that anemia and systemic inflammation, but not arterial circulatory dysfunction, are strong and independent predictors of liver decompensation in outpatients with cirrhosis.
- 23 October 2024
- Published by University Library J. C. Senckenberg
Open AccessEinfluss der systemischen Inflammation für die portalvenöse und systemische Hämodynamik bei Patienten mit Leberzirrhose - Implikationen für hepatische Dekompensation
Systemic inflammation is known to be a key player in the pathogenesis of the development of cirrhosis and consequent liver failure. However, the role of inflammation in the cascade of classical liver decompensation is not fully understood. This research project, part of a series of projects investigating hepatic decompensation in a large cohort of patients, aims to elucidate the interplay between systemic inflammation, hemodynamics, and anemia in decompensation in cirrhosis. The study population consisted of consecutively followed outpatients with advanced liver fibrosis or cirrhosis. We approached our research question by performing a post hoc analysis for potential parameters associated with liver decompensation and/or hospitalization. In total, we analyzed data from 338 patients, with 50/338 (15%) hospitalized for decompensated cirrhosis during a median follow-up of six months. In a first step, we performed a univariate analysis, which showed that active alcoholism (p = 0.002), Model of End-Stage Liver Disease (MELD) score (p = 0.00002), serum IL-6 concentration (p = 0.006), heart rate (p = 0.03), low arterial blood pressure (p < 0.05), maximal portal venous flow (p = 0.008), and low hemoglobin concentration (p < 0.00001) were associated with hospitalization during follow-up. Subsequent multivariate analysis showed an independent association of low hemoglobin (OR = 0.62, 95% CI = 0.51-0.78, p = 0.001) and serum IL-6 concentration (OR = 1.02, 95% CI = 1.01-1.04, p = 0.03), but not hemodynamic parameters, with liver decompensation. An inverse correlation between hemoglobin concentration and portal venous flow (R = -0.362, p < 0.0001) was observed in non-hospitalized patients. The accuracy of baseline hemoglobin levels in predicting hospitalization (area under the curve-AUC = 0.84, p < 0.000001) was high. In conclusion, our study showed that anemia and systemic inflammation, but not arterial circulatory dysfunction, are strong and independent predictors of liver decompensation in outpatients with cirrhosis.
- Open Access
Correction: Sigala et al. A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma. Cells 2022, 11, 1439
The authors made the following changes to their paper
Open AccessCorrection: Sigala et al. A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma. Cells 2022, 11, 1439
The authors made the following changes to their paper
- Open Access
A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma
Adrenocortical carcinoma is a heterogeneous and aggressive cancer that originates from steroidogenic cells within the adrenal cortex. In this study, we have assessed for the preclinical gold standard NCI-H295 in direct comparison with the more recently established MUC-1 and a here newly reported ACC cell line (TVBF-7) the mutational status of important driver genes (TP53, MEN1, PRKAR1A, CTNNB1, APC, ZNRF-3, IGF-2, EGFR, RB1, BRCA1, BRCA2, RET, GNAS and PTEN), Wnt-signaling specificities (CTNNB1 mutation vs. APC mutation vs. wildtype), steroidogenic-(CYP11A1, CYP17A1, HSD3B2, HSD17B4, CYP21A2, CYP11B1, CYP11B2, MC2R, AT1R) and nuclear-receptor-signaling (AR, ER, GCR), varying electrophysiological potentials as well as highly individual hormone secretion profiles (Cortisol, Aldosterone, DHEA, DHEAS, Testosterone, 17-OH Progesterone, among others) which were investigated under basal and stimulated conditions (ACTH, AngII, FSK). Our findings reveal important genetic and pathophysiological characteristics for these three cell lines and reveal the importance of such cell-line panels reflecting differential endocrine functionalities to thereby better reflect clinically well-known ACC patient heterogeneities in preclinical studies.
Open AccessA Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma
Adrenocortical carcinoma is a heterogeneous and aggressive cancer that originates from steroidogenic cells within the adrenal cortex. In this study, we have assessed for the preclinical gold standard NCI-H295 in direct comparison with the more recently established MUC-1 and a here newly reported ACC cell line (TVBF-7) the mutational status of important driver genes (TP53, MEN1, PRKAR1A, CTNNB1, APC, ZNRF-3, IGF-2, EGFR, RB1, BRCA1, BRCA2, RET, GNAS and PTEN), Wnt-signaling specificities (CTNNB1 mutation vs. APC mutation vs. wildtype), steroidogenic-(CYP11A1, CYP17A1, HSD3B2, HSD17B4, CYP21A2, CYP11B1, CYP11B2, MC2R, AT1R) and nuclear-receptor-signaling (AR, ER, GCR), varying electrophysiological potentials as well as highly individual hormone secretion profiles (Cortisol, Aldosterone, DHEA, DHEAS, Testosterone, 17-OH Progesterone, among others) which were investigated under basal and stimulated conditions (ACTH, AngII, FSK). Our findings reveal important genetic and pathophysiological characteristics for these three cell lines and reveal the importance of such cell-line panels reflecting differential endocrine functionalities to thereby better reflect clinically well-known ACC patient heterogeneities in preclinical studies.
- Open Access
Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma Treatment
Current systemic treatment options for patients with adrenocortical carcinomas (ACCs) are far from being satisfactory. DNA damage/repair mechanisms, which involve, e.g., ataxia-telangiectasia-mutated (ATM) and ataxia-telangiectasia/Rad3-related (ATR) protein signaling or ribonucleotide reductase subunits M1/M2 (RRM1/RRM2)-encoded ribonucleotide reductase (RNR) activation, commonly contribute to drug resistance. Moreover, the regulation of RRM2b, the p53-induced alternative to RRM2, is of unclear importance for ACC. Upon extensive drug screening, including a large panel of chemotherapies and molecular targeted inhibitors, we provide strong evidence for the anti-tumoral efficacy of combined gemcitabine (G) and cisplatin (C) treatment against the adrenocortical cell lines NCI-H295R and MUC-1. However, accompanying induction of RRM1, RRM2, and RRM2b expression also indicated developing G resistance, a frequent side effect in clinical patient care. Interestingly, this effect was partially reversed upon addition of C. We confirmed our findings for RRM2 protein, RNR-dependent dATP levels, and modulations of related ATM/ATR signaling. Finally, we screened for complementing inhibitors of the DNA damage/repair system targeting RNR, Wee1, CHK1/2, ATR, and ATM. Notably, the combination of G, C, and the dual RRM1/RRM2 inhibitor COH29 resulted in previously unreached total cell killing. In summary, we provide evidence that RNR-modulating therapies might represent a new therapeutic option for ACC.
Open AccessNovel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma Treatment
Current systemic treatment options for patients with adrenocortical carcinomas (ACCs) are far from being satisfactory. DNA damage/repair mechanisms, which involve, e.g., ataxia-telangiectasia-mutated (ATM) and ataxia-telangiectasia/Rad3-related (ATR) protein signaling or ribonucleotide reductase subunits M1/M2 (RRM1/RRM2)-encoded ribonucleotide reductase (RNR) activation, commonly contribute to drug resistance. Moreover, the regulation of RRM2b, the p53-induced alternative to RRM2, is of unclear importance for ACC. Upon extensive drug screening, including a large panel of chemotherapies and molecular targeted inhibitors, we provide strong evidence for the anti-tumoral efficacy of combined gemcitabine (G) and cisplatin (C) treatment against the adrenocortical cell lines NCI-H295R and MUC-1. However, accompanying induction of RRM1, RRM2, and RRM2b expression also indicated developing G resistance, a frequent side effect in clinical patient care. Interestingly, this effect was partially reversed upon addition of C. We confirmed our findings for RRM2 protein, RNR-dependent dATP levels, and modulations of related ATM/ATR signaling. Finally, we screened for complementing inhibitors of the DNA damage/repair system targeting RNR, Wee1, CHK1/2, ATR, and ATM. Notably, the combination of G, C, and the dual RRM1/RRM2 inhibitor COH29 resulted in previously unreached total cell killing. In summary, we provide evidence that RNR-modulating therapies might represent a new therapeutic option for ACC.
- 15 May 2021
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 73
Endocrine disorders in patients with Fabry Disease: A comprehensive reference center study
Fabry Disease (FD) is a rare X–linked metabolic storage disease characterized by a–galactosidase A deficiency and deficient lysosomal function. The patients suffer from diffuse organ manifestations due to the accumulation of the substrate globotriaosylceramide (Gb3), which are only partially reversed by the available enzyme replacement (ERT) therapies. Previous endocrinological studies in patients with FD included small patient numbers or focused on a certain organ. To investigate the function of the endocrine system in patients with FD, we conducted an observational prospective study and included 77 patients with genetically confirmed FD (26 men, 20/26 classic, 6/26 late–onset phenotype, 51 women, 41/51 and 10/51 respectively), who are systematically followed by our reference center. Within this cohort, 3/77 new cases of subclinical and 2/77 of manifest hypothyroidism were identified while no abnormalities in the GH/IGF-1 axis was found. All (77/77) patients had normal baseline ACTH and morning cortisol levels and unrestricted cortisol response upon short time synacthen testing (62/62). Several cases with altered renin–angiotensin–aldosterone system (RAAS) were detected but none of them included clinical or hormonal suspicion of primary aldosteronism and the discrepancies were explained in the context of chronic kidney disease (CKD) or antihypertensive medications. 11/77 patients were suffering from significant hypophosphatemia (P < 0.80 mmol/l), likely due to VitD deficiency. 25/77 patients had VitD deficiency (25(0H)VitD < 20 mg/l) and 25/77 had insufficiency (25(0H)VitD between 20 and 30 mg/l) despite the fact that 23/50 were substituted with cholecalciferol. In male patients, normal baseline testosterone, FAI and SHBG levels were documented with no indication of hypogonadism. In 1/33 women, primary infertility and estrogen substitution was reported and further 4/33 achieved pregnancy only following IVF. 5/33 patients had a history of miscarriages but all of them delivered children. One/33 women had clinical and biochemical features of PCOS. To our knowledge, this is the largest endocrine study in patients with FD. Our findings indicate presence of a range of endocrine conditions in patients with FD. Longitudinal and case/control studies will be required to provide indication whether these findings are caused by FD dependent mechanisms on endocrine organs or represent independent co-morbidities similar than in the general population. Overall, our study highlights the importance of actively seeking and diagnosing endocrine disorders in patients with FD with the goal to optimise their health care.
- 15 May 2021
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 73
Endocrine disorders in patients with Fabry Disease: A comprehensive reference center study
Fabry Disease (FD) is a rare X–linked metabolic storage disease characterized by a–galactosidase A deficiency and deficient lysosomal function. The patients suffer from diffuse organ manifestations due to the accumulation of the substrate globotriaosylceramide (Gb3), which are only partially reversed by the available enzyme replacement (ERT) therapies. Previous endocrinological studies in patients with FD included small patient numbers or focused on a certain organ. To investigate the function of the endocrine system in patients with FD, we conducted an observational prospective study and included 77 patients with genetically confirmed FD (26 men, 20/26 classic, 6/26 late–onset phenotype, 51 women, 41/51 and 10/51 respectively), who are systematically followed by our reference center. Within this cohort, 3/77 new cases of subclinical and 2/77 of manifest hypothyroidism were identified while no abnormalities in the GH/IGF-1 axis was found. All (77/77) patients had normal baseline ACTH and morning cortisol levels and unrestricted cortisol response upon short time synacthen testing (62/62). Several cases with altered renin–angiotensin–aldosterone system (RAAS) were detected but none of them included clinical or hormonal suspicion of primary aldosteronism and the discrepancies were explained in the context of chronic kidney disease (CKD) or antihypertensive medications. 11/77 patients were suffering from significant hypophosphatemia (P < 0.80 mmol/l), likely due to VitD deficiency. 25/77 patients had VitD deficiency (25(0H)VitD < 20 mg/l) and 25/77 had insufficiency (25(0H)VitD between 20 and 30 mg/l) despite the fact that 23/50 were substituted with cholecalciferol. In male patients, normal baseline testosterone, FAI and SHBG levels were documented with no indication of hypogonadism. In 1/33 women, primary infertility and estrogen substitution was reported and further 4/33 achieved pregnancy only following IVF. 5/33 patients had a history of miscarriages but all of them delivered children. One/33 women had clinical and biochemical features of PCOS. To our knowledge, this is the largest endocrine study in patients with FD. Our findings indicate presence of a range of endocrine conditions in patients with FD. Longitudinal and case/control studies will be required to provide indication whether these findings are caused by FD dependent mechanisms on endocrine organs or represent independent co-morbidities similar than in the general population. Overall, our study highlights the importance of actively seeking and diagnosing endocrine disorders in patients with FD with the goal to optimise their health care.
- 22 December 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 26 (43) , 5609-5616
Premature Adrenarche and its Association with Cardiovascular Risk in Females
Early activation of the adrenal zona reticularis, leading to adrenal androgen secretion, mainly dehydroepiandrosterone sulfate (DHEAS), is called premature adrenarche (PA). The fact that adrenal hyperandrogenism in females has been linked to a cluster of cardiovascular (CV) risk factors, even in prepubertal children, warrants investigation. Controversial results have been obtained in this field, probably due to genetic, constitutional, and environmental factors or differences in the characteristics of participants. In an attempt to understand, in depth, the impact of PA as a potential activator of CV risk, we critically present available data stratified according to pubertal status. It seems that prepubertally, CV risk is increased in these girls, but is somewhat attenuated during their second decade of life. Furthermore, different entities associated with PA, such as polycystic ovary syndrome, non-classical congenital adrenal hyperplasia, heterozygosity of CYP21A2 mutations, and the impact of DHEAS on CV risk, are reviewed. At present, firm and definitive conclusions cannot be drawn. However, it may be speculated that girls with a history of PA display a hyperandrogenic hormonal milieu that may lead to increased CV risk. Accordingly, appropriate long-term follow-up and early intervention employing a patient-oriented approach are recommended.
- 22 December 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 26 (43) , 5609-5616
Premature Adrenarche and its Association with Cardiovascular Risk in Females
Early activation of the adrenal zona reticularis, leading to adrenal androgen secretion, mainly dehydroepiandrosterone sulfate (DHEAS), is called premature adrenarche (PA). The fact that adrenal hyperandrogenism in females has been linked to a cluster of cardiovascular (CV) risk factors, even in prepubertal children, warrants investigation. Controversial results have been obtained in this field, probably due to genetic, constitutional, and environmental factors or differences in the characteristics of participants. In an attempt to understand, in depth, the impact of PA as a potential activator of CV risk, we critically present available data stratified according to pubertal status. It seems that prepubertally, CV risk is increased in these girls, but is somewhat attenuated during their second decade of life. Furthermore, different entities associated with PA, such as polycystic ovary syndrome, non-classical congenital adrenal hyperplasia, heterozygosity of CYP21A2 mutations, and the impact of DHEAS on CV risk, are reviewed. At present, firm and definitive conclusions cannot be drawn. However, it may be speculated that girls with a history of PA display a hyperandrogenic hormonal milieu that may lead to increased CV risk. Accordingly, appropriate long-term follow-up and early intervention employing a patient-oriented approach are recommended.
- Open Access
- 1 August 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (8) , e2853-e2863
Current Management and Outcome of Pregnancies in Women With Adrenal Insufficiency: Experience from a Multicenter Survey
Context: Appropriate management of adrenal insufficiency (AI) in pregnancy can be challenging due to the rarity of the disease and lack of evidence-based recommendations to guide glucocorticoid and mineralocorticoid dosage adjustment. Objective: Multicenter survey on current clinical approaches in managing AI during pregnancy. Design: Retrospective anonymized data collection from 19 international centers from 2013 to 2019. Setting and Patients: 128 pregnancies in 113 women with different causes of AI: Addison disease (44%), secondary AI (25%), congenital adrenal hyperplasia (25%), and acquired AI due to bilateral adrenalectomy (6%). Results: Hydrocortisone (HC) was the most commonly used glucocorticoid in 83% (97/117) of pregnancies. Glucocorticoid dosage was increased at any time during pregnancy in 73/128 (57%) of cases. In these cases, the difference in the daily dose of HC equivalent between baseline and the third trimester was 8.6 ± 5.4 (range 1-30) mg. Fludrocortisone dosage was increased in fewer cases (7/54 during the first trimester, 9/64 during the second trimester, and 9/62 cases during the third trimester). Overall, an adrenal crisis was reported in 9/128 (7%) pregnancies. Cesarean section was the most frequent mode of delivery at 58% (69/118). Fetal complications were reported in 3/120 (3%) and minor maternal complications in 15/120 (13%) pregnancies without fatal outcomes. Conclusions: This survey confirms good maternal and fetal outcome in women with AI managed in specialized endocrine centers. An emphasis on careful endocrine follow-up and repeated patient education is likely to have reduced the risk of adrenal crisis and resulted in positive outcomes.
- 1 August 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (8) , e2853-e2863
Open AccessCurrent Management and Outcome of Pregnancies in Women With Adrenal Insufficiency: Experience from a Multicenter Survey
Context: Appropriate management of adrenal insufficiency (AI) in pregnancy can be challenging due to the rarity of the disease and lack of evidence-based recommendations to guide glucocorticoid and mineralocorticoid dosage adjustment. Objective: Multicenter survey on current clinical approaches in managing AI during pregnancy. Design: Retrospective anonymized data collection from 19 international centers from 2013 to 2019. Setting and Patients: 128 pregnancies in 113 women with different causes of AI: Addison disease (44%), secondary AI (25%), congenital adrenal hyperplasia (25%), and acquired AI due to bilateral adrenalectomy (6%). Results: Hydrocortisone (HC) was the most commonly used glucocorticoid in 83% (97/117) of pregnancies. Glucocorticoid dosage was increased at any time during pregnancy in 73/128 (57%) of cases. In these cases, the difference in the daily dose of HC equivalent between baseline and the third trimester was 8.6 ± 5.4 (range 1-30) mg. Fludrocortisone dosage was increased in fewer cases (7/54 during the first trimester, 9/64 during the second trimester, and 9/62 cases during the third trimester). Overall, an adrenal crisis was reported in 9/128 (7%) pregnancies. Cesarean section was the most frequent mode of delivery at 58% (69/118). Fetal complications were reported in 3/120 (3%) and minor maternal complications in 15/120 (13%) pregnancies without fatal outcomes. Conclusions: This survey confirms good maternal and fetal outcome in women with AI managed in specialized endocrine centers. An emphasis on careful endocrine follow-up and repeated patient education is likely to have reduced the risk of adrenal crisis and resulted in positive outcomes.
- Open Access
- 26 April 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (5) , 1263
Anemia and Systemic Inflammation Rather than Arterial Circulatory Dysfunction Predict Decompensation of Liver Cirrhosis
Background: While systemic inflammation is recognized as playing a central role in the pathogenesis of organ failures in patients with liver cirrhosis, less is known about its relevance in the development of classical hepatic decompensation. Aim: To characterize the relationship between systemic inflammation, hemodynamics, and anemia with decompensation of liver cirrhosis. Methods: This is a post-hoc analysis of a cohort study of outpatients with advanced liver fibrosis or cirrhosis. Results: Analysis included 338 patients of whom 51 patients (15%) were hospitalized due to decompensation of liver cirrhosis during a median follow-up time of six months. In univariate analysis, active alcoholism (p = 0.002), model of end-stage liver disease (MELD) score (p = 0.00002), serum IL-6 concentration (p = 0.006), heart rate (p = 0.03), low arterial blood pressure (p < 0.05), maximal portal venous flow (p = 0.008), and low hemoglobin concentration (p < 0.00001) were associated with hospitalization during follow-up. Multivariate analysis revealed an independent association of low hemoglobin (OR = 0.62, 95% CI = 0.51–0.78, p = 0.001) and serum IL-6 concentration (OR = 1.02, 95% CI = 1.01–1.04, p = 0.03)—but not of hemodynamic parameters—with hepatic decompensation. An inverse correlation between hemoglobin concentration and portal venous flow (R = −0.362, p < 0.0001) was detected for the non-hospitalized patients. Accuracy of baseline hemoglobin levels for predicting hospitalization (AUC = 0.84, p < 0.000001) was high. Conclusion: Anemia and systemic inflammation, rather than arterial circulatory dysfunction, are strong and independent predictors of hepatic decompensation in outpatients with liver cirrhosis.
- 26 April 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (5) , 1263
Open AccessAnemia and Systemic Inflammation Rather than Arterial Circulatory Dysfunction Predict Decompensation of Liver Cirrhosis
Background: While systemic inflammation is recognized as playing a central role in the pathogenesis of organ failures in patients with liver cirrhosis, less is known about its relevance in the development of classical hepatic decompensation. Aim: To characterize the relationship between systemic inflammation, hemodynamics, and anemia with decompensation of liver cirrhosis. Methods: This is a post-hoc analysis of a cohort study of outpatients with advanced liver fibrosis or cirrhosis. Results: Analysis included 338 patients of whom 51 patients (15%) were hospitalized due to decompensation of liver cirrhosis during a median follow-up time of six months. In univariate analysis, active alcoholism (p = 0.002), model of end-stage liver disease (MELD) score (p = 0.00002), serum IL-6 concentration (p = 0.006), heart rate (p = 0.03), low arterial blood pressure (p < 0.05), maximal portal venous flow (p = 0.008), and low hemoglobin concentration (p < 0.00001) were associated with hospitalization during follow-up. Multivariate analysis revealed an independent association of low hemoglobin (OR = 0.62, 95% CI = 0.51–0.78, p = 0.001) and serum IL-6 concentration (OR = 1.02, 95% CI = 1.01–1.04, p = 0.03)—but not of hemodynamic parameters—with hepatic decompensation. An inverse correlation between hemoglobin concentration and portal venous flow (R = −0.362, p < 0.0001) was detected for the non-hospitalized patients. Accuracy of baseline hemoglobin levels for predicting hospitalization (AUC = 0.84, p < 0.000001) was high. Conclusion: Anemia and systemic inflammation, rather than arterial circulatory dysfunction, are strong and independent predictors of hepatic decompensation in outpatients with liver cirrhosis.
- 19 February 2020
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 52 (03) , 179-185
Unfavorable Hormonal and Psychologic Profile in Adult Women with a History of Premature Adrenarche and Pubarche, Compared to Women with Polycystic Ovary Syndrome
If circulating adrenal androgens levels rise before the age of 8 years in girls, this phenomenon is termed premature adrenarche (PA), while the concomitant appearance of pubic hair is called premature pubarche (PP). Girls with PA-PP display an unfavorable hormonal profile compared to their normal peers and have an increased risk of developing polycystic ovary syndrome (PCOS) features peripubertally. However, the sequelae of premature adrenarche remains unclear. We assessed metabolic, hormonal, psychologic profiles, and ovarian morphology in 21 women of mean age (±SD) 21.3±3.3 years, BMI: 23.6±4.4 kg/m2 with PA-PP, 45 women with PCOS and 26 controls, matched for age and BMI. PA-PP women displayed a favorable lipid profile compared to PCOS and controls. Insulin resistance index (HOMA-IR), however, were similar in PA-PP and PCOS women (2.09±1.42, 2.08±0.83) and higher than controls (1.13±0.49, p 3). PA-PP women had a higher score of state/trait anxiety and depressive and eating disorder symptoms than controls, with a pattern that matched that of PCOS women. Only 14% of the PA-PP group fulfilled the Rotterdam PCOS criteria. Some women with a history of PA-PP displayed hormonal and psychologic profile similar to PCOS, and accordingly a regular monitoring of these girls during adulthood is advised.
- 19 February 2020
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 52 (03) , 179-185
Unfavorable Hormonal and Psychologic Profile in Adult Women with a History of Premature Adrenarche and Pubarche, Compared to Women with Polycystic Ovary Syndrome
If circulating adrenal androgens levels rise before the age of 8 years in girls, this phenomenon is termed premature adrenarche (PA), while the concomitant appearance of pubic hair is called premature pubarche (PP). Girls with PA-PP display an unfavorable hormonal profile compared to their normal peers and have an increased risk of developing polycystic ovary syndrome (PCOS) features peripubertally. However, the sequelae of premature adrenarche remains unclear. We assessed metabolic, hormonal, psychologic profiles, and ovarian morphology in 21 women of mean age (±SD) 21.3±3.3 years, BMI: 23.6±4.4 kg/m2 with PA-PP, 45 women with PCOS and 26 controls, matched for age and BMI. PA-PP women displayed a favorable lipid profile compared to PCOS and controls. Insulin resistance index (HOMA-IR), however, were similar in PA-PP and PCOS women (2.09±1.42, 2.08±0.83) and higher than controls (1.13±0.49, p 3). PA-PP women had a higher score of state/trait anxiety and depressive and eating disorder symptoms than controls, with a pattern that matched that of PCOS women. Only 14% of the PA-PP group fulfilled the Rotterdam PCOS criteria. Some women with a history of PA-PP displayed hormonal and psychologic profile similar to PCOS, and accordingly a regular monitoring of these girls during adulthood is advised.
- 1 February 2020
- Published by Elsevier in Diabetes & Metabolism
- Vol. 46 (1) , 1-7
Links between aldosterone excess and metabolic complications: A comprehensive review
- 1 February 2020
- Published by Elsevier in Diabetes & Metabolism
- Vol. 46 (1) , 1-7
Links between aldosterone excess and metabolic complications: A comprehensive review